Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights

-Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARLSBAD, Calif., May 5, 2022 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing…

Click here to view original post